Technology developed at U-M uses sound waves to destroy tissue, providing a new type of cancer therapy

Sparrow Health System, part of University of Michigan Health, experts release findings in a study of a cancer drug for patients with genetic mutations.

Michigan Medicine has developed a new technique that provides a non-invasive alternative to surgery, chemotherapy and radiation treatments for cancer.

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

University of Michigan Rogel Cancer Center researchers are unraveling its nuances, advancing enabling technologies, advocating for patients and figuring out how to ethically integrate this technology into clinical care.

Firearm purchases rose during the pandemic and a survey shows high rates of mental health issues and political extremism among those who bought guns during 2020 and 2021.

A Michigan Medicine expert describes immunotherapy as “the future of cancer treatment” for those who qualify.

Research from experts at Michigan Medicine shows that significant language-based disparities exist in patients’ access to cancer care services, and it’s well before their first appointment with a doctor. 

Cancer survivors who received treatment at the University of Michigan Health Rogel Cancer Center and infusion nurses demystify the experience by providing 10 helpful things to know ahead of time.

Early findings of two studies from the University of Michigan Rogel Cancer Center shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. The papers, published in Cancer and Oral Oncology, offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow, and provide a framework for a new, more sensitive blood test that could help in this monitoring.

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a Michigan Medicine study finds.

Research from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.

A potential drug candidate called ONC201 nearly doubled survival for patients with diffuse midline glioma and DIPG.

A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.

A study from clinicians and researchers at the University of Michigan Rogel Cancer Center reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.